Ischemic heart diseases (IHDs) are leading causes of death globally, and clinical treatment is usually through cardiac surgery to restore the blood flow. However, conventional post-surgery care of IHDs requires complex medical services with unsatisfied therapeutical outcome yet high economic burden. Therefore, the development of a simple and effective post-surgery care strategy for IHDs holds great value for public health. To date, the most convenient route for targeted cardiac treatment is systemic injections. Nanomedicines, where drugs formulated in nanoparticles, have long been clinically applied into targeting various diseases with both clinical and economical success. Herein, we aim to fabricate a cardiac-targeting nanomedicine which will be intravenously injected after the cardiac surgery. The targeted treatment may enhance the drug accumulation in damaged heart, and therefore may improve the clinical outcome comparing to the conventional methods.

2021

2024